Trial Status
Open for enrollment

What is the Purpose of this Study?
This is an observational study to assess depressed mood in patients with relapsing forms of MS who have switched from an Interferon to Aubagio due to symptoms of depression.

Who is Eligible to Participate?
Patients ages 18 to 65 with a diagnosis of relapsing MS, with a Beck Depression score greater than 14, who are switching from an interferon to Aubagio due to symptoms of depression. Patients will also have to meet all inclusion criteria, which will be explained in greater detail by the study coordinator.

What is involved in this Study?
Patients will be prescribed Aubagio, and monitored for 6 months, including lab draws every month. Patients will complete 3 in-person follow up appointments.

How long is the Study?
This study will be approximately 6 months long.

For more information contact:
Lynette McKinney, MSCS, CRC, Study Coordinator at 602-358-2271 or lmckinney@pnal.net